Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02622061 · ClinicalTrials.gov registry record

NIOX VERO Nasal Application in Primary Ciliary Dyskinesia

A clinical trial, sponsored by Aerocrine AB.

Completed
Registry status
163
Enrollment target

NCT02622061: Completed study, sponsored by Aerocrine AB.

NCT02622061 is a clinical trial that has completed, run by Aerocrine AB. The registered enrollment target is 163 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT02622061 has completed, sponsored by Aerocrine AB.

COMPLETED
Registry status
163 participants
Enrollment target

Study Summary

This is a multi-centre, single visit clinical investigation involving patients with known PCD vs. age matched healthy volunteers. This study involves 1 visit which will last one (1) to two (2) hours. Participants (and parent as applicable) will be asked for their consent to participate in the study. A brief medical history will be recorded, including information such as age, gender, height, weight, race, current medications and living environment. If the participant is a PCD patient, they will also be asked about their disease history. Prior to performing the nasal measurements, participants will receive instructions from study personnel and have the opportunity to practice. All participants will have a brief nasal exam and will also have to blow their nose before starting the measurements. Participants will be asked to perform nasal nitric oxide measurements using the tidal breathing method followed by the velum closed with expiration against resistance method. The primary objective is to determine the feasibility and capability of the NIOX VERO to discriminate participants with PCD from those that are healthy. Information collected in this study will help researchers understand more about the diagnosis of and identification of patients with PCD.

Trial Details

FieldValue
Enrollment Target 163 participants
Start Date 2016-05
Est. Completion 2017-04-28
Aerocrine AB

5 total trials

What the finished NCT02622061 record still lists

NCT02622061 is an observational study that tracks outcomes without assigning an intervention. The registered 163 participants enrollment target is mid-sized for trials with a published cap.

The record links to 0 conditions, and to 0 interventions.

NCT02622061 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02622061 about?

NCT02622061 is a clinical study titled "NIOX VERO Nasal Application in Primary Ciliary Dyskinesia". This is a multi-centre, single visit clinical investigation involving patients with known PCD vs. age matched healthy volunteers. This study involves 1 visit which will last one (1) to two (2) hours. Participants (and parent as applicable) will be asked for their consent to participate in the study....

What is the current status of trial NCT02622061?

This trial is currently completed. The enrollment target is 163 participants. The study started on 2016-05. Estimated completion is 2017-04-28.

Who is sponsoring clinical trial NCT02622061?

This trial is sponsored by Aerocrine AB, which has 5 total clinical trials registered on ClinicalTrials.gov.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03180268 · 163 participants · Phase 3

    Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

  • NCT04862221 · 163 participants · Phase 2

    TReatment for ImmUne Mediated PathopHysiology

  • NCT05702229 · 163 participants · Phase 2

    Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

  • NCT06137118 · 163 participants · Phase 1

    AZD0486 as Monotherapy in B-cell Acute Lymphoblastic Leukaemia

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02622061, the US trial registry maintained by the National Library of Medicine. NCT02622061 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.